Previous 10 | Next 10 |
Oakville, Ontario--(Newsfile Corp. - June 9, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treat...
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – According to the World Health Organization , top global killers include heart failure, COPD, cancers, Alzheimer’s, neonatal conditions, and diabetes. Therefore, discovering viabl...
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood sugar must be carefully regulated to ensure the body fu...
Market Movers. Today's Top Stock Picks For New & Trending Opportunities VANCOUVER, BC / ACCESSWIRE / May 27, 2022 / Investors want insight. Welcome to the Market Movers Newsletter where we have created a snapshot of new and trending companies that we think investors will want to know ...
Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treat...
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation . Here we discuss the FDA’s Orphan Drug Designation pro...
Canadian life sciences company Cardiol Therapeutics (NASDAQ:CRDL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug Application (IND) to start a mid-stage trial for oral cannabidiol compound CardiolRx in recurrent pericarditis. Cardiol ...
Third IND authorization for CardiolRx™ in cardiovascular disease Study to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indications Oakville, Ont...
Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked . People with type 2 diabetes are two to four times more likely to develop heart failure than someone without diabetes. Heart failure i...
Gainers: MedAvail Holdings (MDVL) +51%. Borqs Technologies (BRQS) +27%. Verastem (VSTM) +26%. Lexaria Bioscience (LEXX) +22%. Splash Beverage Group (SBEV) +18%. HighPeak Energy (HPK) +17%. Cardiol Therapeutics (CRDL) +16%. Airgain (AIRG) +15%. CoreCivic (CXW) +14%. Renren (RENN) +13%. Losers:...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
Cardiol Therapeutics Inc. Website:
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
2024-06-26 06:30:06 ET B. Riley analyst issues BUY recommendation for CRDL on June 26, 2024 04:52AM ET. CRDL was trading at $2.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations . ...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...